Independence Resources Plc (SNKTY)

[cward]

Independence Resource is still undervalued. Formation Metals has their cobalt mine starting up this year is very close to the Iron Creek project, geology is the same. Formation is valued at a 30 million market cap and was as high as 100 million.

IR should start moving up once the potential from the two mines and the mining contracing business gets noticed.

[cward]

There should be more interest after the second quarter numbers come out in seven weeks. The mining contracting business revenue will show up then.

I saw a video on YouTube with Howard Crosby saying that the cobalt mine, alone, makes IR grossly undervalued. I agree.

[cward]

Looks good now after two years of setting up a mining company. If Grey Eagle mine is starting production later this year and the mining contracting business already producing income it should double or triple the stock price once mining starts.

[donaldflynn]

No posts for 15 months. Even with name change and change in directors...

[wald]

Senetek PLC Embarks on New Strategic Direction

Company Completes $3.0 Million Financing

Chief Executive Officer and Chief Financial Officer Terminated in Connection with Financing

John P. Ryan Appointed Chief Executive Officer in Connection with Financing

Board of Director Resignations and Appointments in Connection with Financing

Company Exits Skin Care Business in Connection with Financing
NAPA, Calif., March 10 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY) today announced the closing of a Security Purchase Agreement, a Note and a Warrant Purchase Agreement DMRJ Group, LLC on March 4, 2010. DMRJ Group, LLC is a Delaware limited liability company affiliated with Platinum Partners Value Arbitrage Fund L.P., an accredited institutional investor with its investment manager headquartered in New York, New York.

The Company issued a Secured Convertible Promissory Note to DMRJ in the principal amount of $3.0 million, which bears no interest and is convertible at a price of $1.25 per share at any time from inception to the fifth anniversary of the Note, at which time conversion is mandatory. Except in the event of default, the Note is not repayable in cash. In addition, the Company issued a five-year warrant to purchase 1.8 million of the Company's ordinary shares at an exercise price of $1.75 per share.

In connection with the financing and sale of the skin-care business, Frank J. Massino was terminated without cause as Chief Executive Officer and resigned as Chairman of the Board of Directors. Mr. Massino has been retained as a part-time consultant for a three year period to assist in management of certain of the Company's existing investments and interests. Also, in connection with the financing and sale of the skin-care business, William F. O'Kelly was terminated without cause as Chief Financial Officer and Mr. Rodger Bogardus resigned from the Board of Directors.

John P. Ryan has been appointed to succeed Mr. Massino as Chief Executive Officer and Chairman of the Board of Directors. Mr. Ryan has extensive management experience in the mining industry, and in the past has been Founder and Chairman of U.S. Silver Corporation, a Toronto Stock Exchange listed company, where he earlier served as Chief Financial Officer. Mr. Ryan was a Founder, Secretary and Chief Financial Officer of High Plains Uranium, from inception on February 2005 to September 2006. In collaboration with principals from Platinum, he was a founder and principal of Platinum Diversified Mining, a resource focused $85 million SPAC which listed on the London AIM in 2006. He received a B.S. degree in Mining Engineering from the University of Idaho and a JD from Boston College Law School.

In addition, Mr. Howard Crosby has been appointed to the Board of Directors and named President of the Company. Mr. Crosby has extensive experience working with public companies. He was a founding Director of White Mountain Titanium Corporation, a founder and Director of High Plains Uranium, and also a founder of Platinum Diversified Mining. He is currently the Chairman of Plasmet Corp., a private green energy company. Mr. Crosby graduated from the University of Idaho in 1974.

Dr. Wesley Holland has also been appointed to the Board of Directors. Dr. Holland has nearly 30 years of experience in diagnostic radiology. He was licensed in California from 1981 to 1994 and is currently licensed in South Carolina and in Florida. His specific expertise is in utilizing critical molecular and nuclear diagnostic imaging procedures to diagnose and treat disease and disorders such as heart disease and cancer.

The Company received reports on November 13, 2009 and on February 1, 2010 from Miller Tabak + Co., LLC, prepared in their capacity as financial advisors to the Board of Directors, which reviewed strategic options and the best means to development of a business plan to maximize the assets of the company. Observations made by Miller Tabak included the following:

•The Company's current businesses are all underfunded intellectual property assets that will require investments far in excess of existing Company resources to bring to the point where they would generate meaningful revenue.
•Establishment of competitive sales and marketing infrastructure generating meaningful revenue would require investment far in excess of existing Company resources.
•The Company has realized past success with intellectual property licensing but this business model is in disfavor with institutional investors which makes it difficult to create a viable market for the Company's stock.
•Skincare is a highly competitive, highly fragmented market with few barriers to entry for the over-the-counter and cosmetic market.


Based on these observations, Miller Tabak recommended that the Board develop a new business strategy to bring revenue, profits and a positive opportunity for Company shareholders. In addition, a condition precedent to the financing was the divestiture of the skin care business.

With consideration to the strategic review by Miller Tabak and the condition to the transaction with DMRJ, the Company executed an Asset Purchase Agreement and a Note with Skinvera LLC, a company wholly owned by Frank J. Massino, former Chairman and Chief Executive Officer of the Company, whereby Skinvera purchased all assets and assumed all existing liabilities of the Company's skincare business (except for assets and liabilities related to kinetin and zeatin) and received $1.8 million in cash in return for a $1.8 million Secured Promissory Note which bears interest at 6% per annum and is due on the seventh anniversary of the Note. The Asset Purchase Agreement includes provisions for royalty payments to the Company from Skinvera based on 5% of net direct sales of skincare products and 10% of net skincare royalties; up to a maximum of $5 million.

Mr. Ryan, Senetek's new Chairman and Chief Executive Officer, stated, "I am very pleased to have been given the opportunity to set a new business path for Senetek. Our team is currently evaluating a number of potential value creating transactions which are consistent with our focus to maximize shareowner value. I am also looking forward to working with the Board in optimizing the value of the biotech assets the Company currently holds. The sale of the skin-care assets is a first step in an ongoing process of finding good matches for our existing technology. As we develop a new strategic direction for the Company, we look forward to communicating our plans to our shareholders and the investment community."

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008 and subsequent Quarterly Reports on Form 10-Q. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


SOURCE Senetek PLC

[MinnieM]

http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=snkty

[MinnieM]

fully reporting too.

[MinnieM]

admin needs to correct name on here for quote box to work properly

[MinnieM]

been moving nicely

[MinnieM]

SNKTY...Chart... You don't seem to have a chart in your ibox. Here's one for you:










"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

[BioSpecialist]

Stock recommendation: Senetek PLC (sntky.ob)



We believe this stock is great buy at this very low price, and has lots of potential for a large upwards move in stock price in the range $3-10 in 2010 (250%-700%)

Senetek Fact Sheet

This is a very undervalued stock which has been living a quiet life on Nasdaq.

As of today (1. November 2009) it is priced at 1.3, which is less than the book value of the company!

Senetek has $12 million in cash and no debt! With about 8.5 million shares, it gives a P/B ratio of 12/8.5=1.41

Senetek PLC has a very valuable product and patent portfolio, from which it could gain hugh rises in profits over the next 1-5 years.
The company operates in two segments,

Skincare and Pharmaceutical:

Skincare

The Skincare segment offers Pyratine-6, a second generation cytokinin for the treatment of aging skin;
Pyratine XR for the visible signs and symptoms associated with various conditions, such as rosacea, eczema, contact dermatitis, and menopause;
(These have already been launched in 2009)

4HBAP, an aromatic cytokinin for the treatment of photodamaged skin and its effect on the reduction of erythema; and
(To marked in 1Q 2010)

Kinetin, a first generation cytokinin that is a plant growth factor, which retards senescence of plants and delays age-related changes in cultured human skin cells.
(Sold rights to Kinetin to VALEANT PHARMA which has had a hugh succes with it in the product line Kinerase)

Pharmaceutical:
The Pharmaceutical segment offers Invicorp, an intracavernous injection therapy for the treatment of male erectile dysfunction;
In has been approve for sale in Denmark, and partly in the UK. Pending PDA approval in US

Reliaject, an autoinjector system; and diagnostic monoclonal antibodies that are used in Alzheimer’s and other disease research.

Research
The company has research and collaboration agreements with the Institute of Experimental Botany in Prague, the Czech Republic for the research on plant physiology, genetics, and biotechnology;
Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland for the rights to three compounds for the treatment of skin aging, and technology used for the treatment of brain tumors using interference RNA; and PROTEOMAGE, the European integrated project on healthy aging.

It operates primarily in the United States, the United Kingdom, and Denmark. Senetek PLC was founded in 1983 and is headquartered in Napa, California.


Why is Senetek a great buy?

No matter which if the strategies below Senetek chooses in 2009 - 2010, it will push the price of the stock to a much higher level:

* It keeps it independency and let its sales grow organically. (likelihood 25%) (slower but steady rise in the share price in 2010, price $2-5 )
* It may sell of the Invicorp and Reliaject products and focus on the skincare sales, (likelihood 25%) (jump in price, and then slower but steady rise in the share price in 2010, a jump to $3-4 then move steadily to $6-7)
* May want merge, be bought by a larger skin-care company to better utilize sales channels, marketing etc. (likelihood 50%)(Large jump in price, $6-10)


and

* It has a shareholder approved share buy-back plan put in to place, which may start at any time.
* Senetek will move listing to a larger exchange in the future, this alone will boost the stock price
* The CEO has a large amount of shares and options and has very strong incentives to move the stock price to a much higher level

[BioSpecialist]

EU-Approval soon

Market-cap only 10,6 M$ ..

[BioSpecialist]

SENETEK IS MASSIVE UNDERVALUED !!!

Mcap 10 M$
Cash 13 M$

Fact Sheet ...Check Out
http://www.senetekplc.com/Senetek_Fact_Sheet-pdf.pdf

Senetek PLC Acquires Rights To Additional Anticancer RNAi Technology


Senetek PLC announced an agreement with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland for the exclusive rights to a new and promising tumor treatment using an RNAi based therapeutic technology for the potential use against a broad range of cancers. This technology, which specifically targets a cancer biomarker, was developed by the Institute in cooperation with Department of Neurosurgery and Neurotraumatology University of Medical Sciences in Poznan, Poland. Under the terms of the collaborative agreement, Senetek will have rights for all applications of the in-licensed technologies in exchange for undisclosed royalty payments to be paid to the Institute upon commercialization.

[BioSpecialist]

BREAK OUT SOON

http://www.senetekplc.com/Senetek_Fact_Sheet-pdf.pdf

[BioSpecialist]

RALLY WILL START SOON :::

[BioSpecialist]

US-Partner for Invicorp soon

Big news coming soon !!!

glta

[BioSpecialist]

More EU Approvals coming soon ::

Market Cap of 10 M$ is a Joke ...
Cash 13 M$


The Company reported that there continues to be great interest in Invicorp® for the European Market and that the Company is diligently working to restore an out-of-stock situation due to its former licensee, Ardana BioScience Limited, entering receivership. Senetek expects to have finished product manufactured in the fourth quarter of 2009 and, thus, to begin receiving corresponding revenues for Named Patient Supplies in the UK and commercial sales in Denmark. The Company noted a recent addition to the general approval process in Europe that could impact future sales of Invicorp, creating a potential opportunity to accelerate approval in some countries such as Turkey, a country with a population of more than 36 million males. Invicorp is a highly safe and effective treatment for erectile dysfunction ("ED") that has received marketing authorization in Denmark and authorization for Named Patient Supply in the UK.

"The second quarter saw the Company take a variety of actions aimed at preparing for sales growth as we initiated the rollout of clinically-proven PyratineXR, our next generation Cytokinin-based skincare technology, into the marketplace," said Frank Massino, Chairman and CEO, Senetek PLC. "We enter the second half of the year with focus and momentum as we launch our first marketing campaign for PyratineXR, which has been shown to be highly beneficial for all skin types, while being ideal for sensitive skin caused by inflammatory skin conditions such as rosacea and acne, which result in facial redness in millions of people."

On July 22, 2009, the Company announced that PyratineXR is now available nationwide through select dermatologists and other physicians. The launch is being supported by conventional and new line media advertising in select markets nationwide. To view copies of the ads, visit http://www.senetekplc.com/ads. The Company expects to launch a comprehensive new website for PyratineXR, incorporating product information, educational resources and e-commerce capabilities among other features, during the third quarter at www.PyratineXR.com.

During the second quarter, a clinical study entitled "Topical PRK-124 (0.125%) Lotion for Improving the Signs and Symptoms of Rosacea," was published in the Journal of Drugs in Dermatology, a prestigious peer-reviewed dermatological publication (May 2009). The 12-week, open-label study concludes that PyratineXR (0.125% furfuryl tetrahydropyranyladenine) improved skin barrier function and the appearance of erythema (redness) and lesions (pustules and papules) associated with mild-to-moderate rosacea during 12 weeks of treatment.

In the latter stages of the quarter, Senetek opened its new Customer Care Center in Brentwood, TN to support the national rollout of PyratineXR as well as Pyratine-6. The Customer Care Center, located outside of Nashville, provides doctors (dermatologists, plastic surgeons, etc.) and others who provide PyratineXR and Pyratine-6 to consumers an on-call resource to answer any questions related to the products and for sales, distribution and fulfillment. Consumers can call the Customer Care Center to find Pyratine products in their hometowns, to have questions answered and to place orders. The Customer Care Center is led by Mark Ryals, Director of Customer Service, who brings nearly 25 years of pharmaceutical and related customer service and sales experience to Senetek. Ryals spent 12 years working with GlaxoSmithKline's dermatology portfolio.

In early June, Senetek announced a six year extension of existing rights under its agreement with the Czech Republic Institute of Experimental Botany to receive exclusive global licenses, for all applications, to any cytokinin developed, in-licensed or otherwise acquired by the Institute and the right to co-exploit with the Institute any cytokinins that Senetek does not elect to in-license. Senetek also has a right of first refusal before the Institute can license any of its non-cytokinin compounds to any third party for cosmeceutical or anti-aging dermatological applications. In addition, a new group of compounds, "supercytokin plus", has been added to the agreement. The Institute will also perform enhanced research activities in the areas of pre-selective assay, development of analytical methods, stability testing, large scale synthesis and molecular mechanism of action. Visit the Institute's website at www.ueb.cas.cz.

Clinical studies demonstrate that PyratineXR is an anti-aging compound that can help "Beat Red" with 67% less redness, 84% smoother skin and 41% more moisture. Physician-strength PyratineXR is clinically proven to relieve redness (erythema), soothe irritation, increase moisture and repair damaged skin quickly and effectively. Clinical studies have demonstrated that PyratineXR significantly reduces the appearance of lesions (papules and pustules), spider veins and dark spots. In addition, PyratineXR improves skin texture in just days while improving dry, flaky skin by restoring the skin's barrier function and increasing moisture retention. PyratineXR offers an option for inflammatory skin conditions such as rosacea, acne, sunburn and razor burn.

PyratineXR is available as a Lotion or Creme through select physicians throughout North America. Senetek plans to introduce three new products for PyratineXR later this year. For more information or to find a PyratineXR Physicians Network doctor, call 1-888-467-9728 or visit www.PyratineXR.com. To watch a brief video news segment about PyratineXR, visit www.youtube.com/watch?v=i8oa3N99e_o.

[BioSpecialist]

Senetek PLC Rated 'Strong Buy' by Wharton Capital Management

Senetek PLC (Nasdaq: SNTKY) that New York City-based Wharton Capital Management Inc., has initiated coverage of Senetek with a "strong buy" rating on the company.

"Our price target is $10," said Wharton Capital Management analyst Rick Joshi. "We believe that Senetek is grossly undervalued at current levels.

"Senetek has a profitable Cosmeticals business with substantial and rapidly growing sales," Joshi continued. "It has in the late stages of development a novel biopharmaceutical for treating ED (Erectile Dysfunction) with a proprietary, advanced drug delivery system that targets

[BioSpecialist]

Senetek will be the next Psivida !!!!

THIS UNDERVALUED STOCK IS FLYING UNDER RADAR !!!

Senetek (SNKTY.OB)

Market Cap : 9 M$
Cash : 13 M$ (NO DEBT)
Price : 1,20 $

Shares Out : 7,65 Mio

Pipeline
http://www.senetekplc.com/view_our_pipeline.asp

Analyst Report ..Read
http://www.senetekplc.com/SenetekPLC-IntelligenceDynamicsResearchReport.pdf


Senetek PLC
(OTC Bulletin Board: SNKTY.OB)
Senetek is a Life Sciences company engaged in the development of technologies
that target the science of healthy aging. The Company’s extensive research
collaborations have resulted in a strong pipeline of patented compounds and
products with broad therapeutic applications and a leading presence in
dermatology. Senetek collaborates with established specialty pharmaceutical
companies in the final development and marketing of its proprietary products, most
recently resulting in the development of the best-selling anti-aging product sold in
the North American physician market.
Lead Products
Pyratine-6™
(0.1% Furfuryl Tetrahydropyranyladenine)
The first in Senetek’s new generation cytokinin pipeline to complete development,
Pyratine-6™ has demonstrated, through clinical trials, superior results and faster
onset of action in treating photodamaged skin when compared to Senetek’s highly
successful predecessor compounds.
In September 2008, Senetek launched the Pyratine-6™ family of products in the
North America Physician market.
The Company is actively seeking marketing collaboration agreements for other
geographies.
Pyratine XR™
(0.125% Furfuryl Tetrahydropyranyladenine)
Based on positive results demonstrated in Pyratine-6™ clinical evaluations,
Senetek initiated a clinical trial of 0.125% Furfuryl Tetrahydropyranyladenine for
the reduction of visible signs and symptoms associated with various conditions
such as rosacea, eczema, contact dermatitis and menopause. Rosacea is a chronic
dermatosis afflicting more than 14 million people in North America and 45 million
people worldwide.
An overall clinical improvement was noted in 80% of subjects, including reduction
of erythema and papules. The investigators saw continual, statistically significant
mean improvement with Pyratine XR™ treatment, including a 90% improvement
in lesions, 45% improvement in erythema and a 28% improvement in
telangiectasia
Pyratine XR™ Crème and Lotion were launched in the North American Physician
market in March 2009.
The Company is actively seeking marketing collaboration agreements for other
geographies
Kinetin
Senetek scientists developed and patented the cytokinin Kinetin as an anti-aging
compound. Senetek commercialized Kinetin under the Kinerase® trademark, which
is now owned by Valeant Pharmaceuticals Inc. Kinerase® is currently the leading
anti-aging compound sold in the North American physician market. In early 2007,
Senetek sold Valeant a perpetual use license for Kinetin for $21 million,
forgiveness of a $6 million prepaid royalty credit reimbursement obligation that
Senetek otherwise would have owed to Valeant, and a right to share in future
royalties due to Valeant from other Kinetin licensees through 2011.

Invicorp®
Senetek has entered into a partnership agreement with Plethora Solutions
Limited (LSE-AIM: PLE), for the commercialization of Invicorp® in North
America. Under this agreement, Plethora assumes full financial responsibility
for all future development, regulatory approvals, and sales and marketing of the
product. Senetek will participate in the success of Invicorp® through milestone
payments and royalties based on net sales. The European marketing rights,
previously licensed to Ardana Biosciences Ltd, were returned to Senetek when
Ardana entered receivership in June 2008. An evaluation of the Company’s
options regarding redeployment of the European marketing rights as well as
rights for the rest of the world is currently underway.
Reliaject®
Reliaject® is an advanced drug delivery system for self-administration of
parenteral drugs, including epinephrine for emergency treatment of anaphylaxis,
a severe allergic reaction that occurs in response to food, insect venom or
medication – currently a $250 million market in North American alone.
Reliaject® is also well suited to other injectable therapies including Senetek’s
Invicorp® for the treatment of ED. The company entered an agreement with
Ranbaxy Pharmaceuticals, through which Senetek will receive future milestone
payments, as well as royalties paid out over 15 years on all products introduced
in the Reliaject® drug delivery system.
Research & Development
Senetek’s scientific research collaborations form the basis for a continuous,
interactive flow of new product identification, evaluation and testing activity
between the University of Aarhus, Senetek’s dedicated laboratory in Denmark,
the Institute of Experimental Botany in the Czech Republic, the University of
California-Irvine, and the Institute of Bioorganic Chemistry of the Polish
Academy of Sciences among others. Through these collaborations the Company
has greatly expanded its IP portfolio, adding many vital technologies, while
accelerating product development.
Pipeline
Senetek’s partnerships with leading research and academic institutions have
placed the Company at the forefront of technological advancements in the
science of aging. The Company’s large and growing IP portfolio features new
models in treatment that span a range of therapeutic areas including
dermatology, nutrition, wound healing and erectile dysfunction.
Market Opportunity
Owing to an increase in health awareness and continued progress in the field of
science and medicine, the average global life span has seen a steady rise over the
past several decades, a trend that is only expected to become more pronounced
in the decades to come. According to the United Nations, the percentage of the
world’s population over the age of 60 is expected to rise from 10.0% in 2000 to
22.1% in 2050. In more developed regions, such as Europe and North America,
these percentages are anticipated to be even higher, estimated at approximately
35.0% and 27.0%, respectively, by 2050. The aging of society is likely to create
increased opportunity for treatments and therapies such as those based on
Senetek’s patented compounds.
Business Model
With a strong balance sheet in place, the Company has transitioned from a
licensing model to a sales and marketing model, delivering an increased revenue
stream with higher margin potential and creating long-term value for its
shareholders.